

# Gastroenteropancreatic Neuroendocrine Tumors

Ca-A Cancer Journal for Clinicians

68, 471-487

DOI: [10.3322/caac.21493](https://doi.org/10.3322/caac.21493)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 72.	1.3	7
2	&lt;p&gt;Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1799-1807.	0.8	7
3	Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors. <i>Endoscopy International Open</i> , 2019, 07, E1393-E1399.	0.9	25
4	Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. <i>Frontiers in Endocrinology</i> , 2019, 10, 682.	1.5	52
5	Difference in survival between right- versus left-sided colorectal neuroendocrine neoplasms. <i>Journal of Zhejiang University: Science B</i> , 2019, 20, 933-939.	1.3	2
6	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. <i>Neuroendocrinology</i> , 2019, 109, 83-99.	1.2	87
7	Cystic pancreatic neuroendocrine tumors: A distinctive subgroup with indolent biological behavior? A systematic review and meta-analysis. <i>Pancreatology</i> , 2019, 19, 738-750.	0.5	11
8	Molecular imaging and therapy of somatostatin receptor positive tumors. <i>Clinical Imaging</i> , 2019, 56, 146-154.	0.8	28
9	Neuroendocrine Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1053-1054.	0.9	0
10	Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2019, 5, 489.	3.4	2
11	Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 1126-1135.	0.5	10
12	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 377-383.	1.2	15
13	A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study. <i>Future Oncology</i> , 2020, 16, 4369-4379.	1.1	2
14	Rectal NETs and rectosigmoid junction NETs may need to be treated differently. <i>Cancer Medicine</i> , 2020, 9, 971-979.	1.3	8
15	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 130.	6.9	166
16	Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. <i>BMC Cancer</i> , 2020, 20, 1002.	1.1	13
17	Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?. <i>Nuclear Medicine Communications</i> , 2020, 41, 1034-1039.	0.5	28
18	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	157.7	237

#	ARTICLE	IF	CITATIONS
19	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.	1.0	23
20	Liver Transplantation for Neuroendocrine Metastases. <i>Current Transplantation Reports</i> , 2020, 7, 317-323.	0.9	0
21	<p>Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6727-6737.	0.9	7
22	Orai3: Oncochannel with therapeutic potential. <i>Cell Calcium</i> , 2020, 90, 102247.	1.1	20
24	Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 28.	2.0	21
25	Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 997-1009.	1.1	4
27	mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). <i>Frontiers in Endocrinology</i> , 2020, 11, 562505.	1.5	25
28	Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. <i>Diagnostics</i> , 2020, 10, 881.	1.3	7
29	Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. <i>Nutrition and Cancer</i> , 2020, , 1-10.	0.9	4
30	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	1.2	13
31	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	1.5	1
32	Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma. <i>American Journal of Roentgenology</i> , 2020, 215, 390-397.	1.0	8
33	Primary left ventricular neuroendocrine tumor in a middle-aged female: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 653-653.	0.7	0
34	Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. <i>Pancreatology</i> , 2020, 20, 875-879.	0.5	14
35	Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093211.	0.4	7
36	A rare case of severe hypertension with hypokalemic metabolic alkalosis in a 14-year-old girl: Answers. <i>Pediatric Nephrology</i> , 2020, 35, 1633-1638.	0.9	0
37	Development and Validation of a Prognostic Nomogram to Guide Decisionâ€Making for Highâ€Grade Digestive Neuroendocrine Neoplasms. <i>Oncologist</i> , 2020, 25, e659-e667.	1.9	12
38	Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoidsâ€â€What Is the Relationship?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 662.	1.8	35

#	ARTICLE	IF	CITATIONS
39	The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors. <i>European Journal of Radiology</i> , 2020, 124, 108847.	1.2	10
40	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , 2020, 12, 1021.	1.7	17
41	Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience. <i>Neuroendocrinology</i> , 2021, 111, 304-319.	1.2	18
42	Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. <i>ESMO Open</i> , 2020, 5, e000632.	2.0	14
43	Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2217-2228.	1.8	22
44	Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 54-54.	1.5	29
45	Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest. <i>Neuroendocrinology</i> , 2021, 111, 490-504.	1.2	14
46	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021, 44, 989-994.	1.8	18
47	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 811-818.	1.8	2
48	Sensitivity and Specificity of the NETest: A Validation Study. <i>Neuroendocrinology</i> , 2021, 111, 580-585.	1.2	6
49	Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine</i> , 2021, 71, 242-252.	1.1	5
50	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021, 53, 171-182.	0.4	45
51	Prediction of the World Health Organization Grade of rectal neuroendocrine tumors based on CT histogram analysis. <i>Cancer Medicine</i> , 2021, 10, 595-604.	1.3	9
52	Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is $\geq 10\%$ ?. <i>Oncologist</i> , 2021, 26, 294-301.	1.9	17
53	A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 215-220.	1.2	11
54	High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour. <i>Endocrine</i> , 2021, 71, 494-501.	1.1	8
55	Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. <i>Oncology Research and Treatment</i> , 2021, 44, 276-280.	0.8	2
56	Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor. <i>International Journal of Biological Sciences</i> , 2021, 17, 3760-3775.	2.6	22

#	ARTICLE	IF	CITATIONS
57	Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. <i>Annals of Surgical Oncology</i> , 2021, 28, 1950-1958.	0.7	10
58	Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	1.4	16
59	Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12936.	1.2	3
60	Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. <i>Medicine (United States)</i> , 2021, 100, e24223.	0.4	4
61	Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors. <i>Cureus</i> , 2021, 13, e12640.	0.2	4
62	Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. <i>BMC Cancer</i> , 2021, 21, 10.	1.1	6
63	Gastroenteropancreatic neuroendocrine tumors. , 2021, , 181-200.		0
64	Gastroduodenal NETs. , 2021, , 107-124.		0
65	Recent capability of diagnosis and treatment of gastrinoma: a clinical case report. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 50.	0.2	0
66	New Surgical Strategies. , 2021, , 113-128.		0
67	The clinical characteristics and survival associations of pancreatic neuroendocrine tumors: does age matter?. <i>Gland Surgery</i> , 2021, 10, 574-583.	0.5	1
68	Neuroendocrine tumor of thoracic spine: case report and literature review. <i>Translational Cancer Research</i> , 2021, 10, 1177-1182.	0.4	1
69	Cardiac Metastasis Caused Fatal Ventricular Arrhythmia in a Patient with a Rectal Neuroendocrine Tumor. <i>Internal Medicine</i> , 2021, 60, 373-378.	0.3	3
70	Primary versus secondary nature of mesenteric neuroendocrine tumours. <i>BMJ Case Reports</i> , 2021, 14, e239217.	0.2	1
71	Treatment personalization in gastrointestinal neuroendocrine tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 29.	1.3	10
72	A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. <i>Journal of Gastroenterology</i> , 2021, 56, 395-405.	2.3	16
73	CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. <i>Molecular Cancer</i> , 2021, 20, 51.	7.9	71
74	Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. <i>Current Oncology Reports</i> , 2021, 23, 43.	1.8	131

#	ARTICLE	IF	CITATIONS
75	Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 231-255.	0.8	19
76	Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System. <i>Frontiers in Endocrinology</i> , 2021, 12, 652363.	1.5	26
77	Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. <i>Cureus</i> , 2021, 13, e14006.	0.2	4
78	Roles of the nervous system in pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 623-633.	1.2	11
79	Image Quality and Detection of Small Focal Liver Lesions in Diffusion-Weighted Imaging. <i>Investigative Radiology</i> , 2021, 56, 579-590.	3.5	5
80	Neuroendocrine liver metastases: The role of liver transplantation. <i>Transplantation Reviews</i> , 2021, 35, 100595.	1.2	4
81	Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	2
82	Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with <sup>177</sup> Lu-DOTATATE. <i>Endocrine Connections</i> , 2021, 10, 422-431.	0.8	5
83	From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 654660.	2.2	4
84	A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study. <i>Neuroendocrinology</i> , 2022, 112, 263-275.	1.2	3
85	Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 155-161.	0.9	8
86	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 615-636.	2.6	21
87	Cardiac Imaging in Carcinoid Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2240-2253.	2.3	8
88	Spontaneous intra-abdominal hemorrhage of a well-differentiated, grade 3 gastric neuroendocrine tumor during drug-based treatment. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1244-1249.	0.4	2
89	Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment. <i>Frontiers in Endocrinology</i> , 2021, 12, 658392.	1.5	4
90	Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 719-726.	0.5	5
91	Endoscopic and surgical treatment of T1N0M0 colorectal neuroendocrine tumors: a population-based comparative study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 2488-2498.	1.3	6
92	Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI: A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. <i>Cancers</i> , 2021, 13, 2726.	1.7	9

#	ARTICLE	IF	CITATIONS
93	Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 577517.	2.2	15
94	Role of lymphatic endothelial cells in the tumor microenvironment—a narrative review of recent advances. <i>Translational Lung Cancer Research</i> , 2021, 10, 2252-2277.	1.3	17
95	TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGF $\beta$ 2 signaling in gastroenteropancreatic neuroendocrine neoplasms. <i>Aging</i> , 2021, 13, 14065-14077.	1.4	5
96	Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 681149.	1.3	4
97	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). <i>Annals of Surgical Oncology</i> , 2021, 28, 7506-7517.	0.7	25
98	Neuroendocrine Tumours: a Literature Review. <i>Kreativna Ć Hirurģi Ć I Onkologi Ć</i> , 2021, 11, 174-182.	0.1	0
99	Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 917-926.	1.1	9
100	Recent progress in SRC targeted therapy for pancreatic cancer. <i>World Chinese Journal of Digestology</i> , 2021, 29, 621-627.	0.0	1
101	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021, 9, 423-438.	1.1	3
102	The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study. <i>Cancer Reports</i> , 2022, 5, e1462.	0.6	4
103	The concept of the "carcinoid™": The phylogenic and ontogenic evolution of the unresolved karzinoide conundrum. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 258-267.	0.6	0
104	Neuroendocrine tumors in Panama: A nationwide database analysis. <i>Molecular and Clinical Oncology</i> , 2021, 15, 157.	0.4	2
105	A Case of Profound Secretory Diarrhea Revealing 2 Primary Neuroendocrine Tumors. <i>ACG Case Reports Journal</i> , 2021, 8, e00625.	0.2	1
106	Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 197-206.	0.8	5
107	Nonviral siRNA delivery systems for pancreatic cancer therapy. <i>Biotechnology and Bioengineering</i> , 2021, 118, 3669-3690.	1.7	13
108	Mixed Neuroendocrine Carcinoma and Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Frontiers in Surgery</i> , 2021, 8, 678853.	0.6	5
109	Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1323-1329.	2.8	31
110	<sup>177</sup> Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. <i>JCO Global Oncology</i> , 2021, 7, 1167-1175.	0.8	10



#	ARTICLE	IF	CITATIONS
111	A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. <i>EJNMMI Research</i> , 2021, 11, 73.	1.1	7
112	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 707214.	1.3	26
113	Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124750.	2.8	98
114	Risk Factors and Predictive Score Model for Early Recurrence After Curative Surgery in Patients With Poorly Differentiated Gastrointestinal Neuroendocrine Neoplasms. <i>Frontiers in Surgery</i> , 2021, 8, 703138.	0.6	0
115	Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 85-90.	0.6	5
116	PET/CT Variants and Pitfalls in Liver, Biliary Tract, Gallbladder and Pancreas. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 502-518.	2.5	3
117	Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, , 1-6.	1.4	2
119	The role of biomarker in pancreatic neuroendocrine tumor. <i>Journal of Pancreatology</i> , 2021, Publish Ahead of Print, .	0.3	0
120	New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification [ ]. <i>Cancer Letters</i> , 2021, 518, 207-213.	3.2	6
121	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13041.	1.2	3
122	Stem/progenitor cells in normal physiology and disease of the pancreas. <i>Molecular and Cellular Endocrinology</i> , 2021, 538, 111459.	1.6	6
123	Tumor Heterogeneity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. <i>Endocrines</i> , 2021, 2, 28-36.	0.4	2
124	Cancer Beliefs Associated with Posttraumatic Stress Disorder in Neuroendocrine Tumor Survivors. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 369-373.	0.6	2
125	Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	15
126	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
127	Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study. <i>Medical Science Monitor</i> , 2020, 26, e923375.	0.5	10
128	Clinicopathological features and survival for gallbladder NEN: a population-based study. <i>Endocrine Connections</i> , 2019, 8, 1273-1281.	0.8	18
129	What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. <i>Oncotarget</i> , 2020, 11, 3751-3752.	0.8	2



#	ARTICLE	IF	CITATIONS
130	Analysis of 72 patients with colorectal high-grade neuroendocrine neoplasms from three Chinese hospitals. <i>World Journal of Gastroenterology</i> , 2019, 25, 5197-5209.	1.4	10
131	Gastrointestinal neuroendocrine tumors in 2020. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 791-807.	0.8	119
132	Clinicopathological Spectrum of Primary and Metastatic Neuroendocrine Neoplasms. <i>Cureus</i> , 2020, 12, e11764.	0.2	4
133	Pancreatic neuroendocrine tumor with ectopic adrenocorticotrophic hormone syndrome: a case report and 5-year follow-up. <i>Endocrine Journal</i> , 2022, 69, 243-251.	0.7	2
134	Evaluation of Pathologic Prognostic Factors in Neuroendocrine Tumors of the Small Intestine. <i>American Journal of Surgical Pathology</i> , 2022, 46, 547-556.	2.1	3
135	Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
136	Incidental nonfunctioning pancreatic neuroendocrine tumors: Contrast enhanced ultrasound features in diagnosis. <i>Clinical Hemorheology and Microcirculation</i> , 2022, 80, 343-352.	0.9	5
137	Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1479.	0.8	7
138	Insight into gastrointestinal heterotopic pancreas: imaging evaluation and differential diagnosis. <i>Insights Into Imaging</i> , 2021, 12, 144.	1.6	10
139	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103493.	2.0	4
140	Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms. <i>Advances in Clinical Medicine</i> , 2019, 09, 225-234.	0.0	0
141	<i>Neue Arzneimittel 2018.</i> , 2019, , 61-175.		1
142	Primary neuroendocrine tumor in the presacral region: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 1884-1891.	0.3	2
143	&lt;p&gt;Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9663-9668.	1.0	1
144	Myocardial uptake of <sup>68</sup> Ga-DOTATATE: correlation with cardiac disease and risk factors. <i>Acta Radiologica</i> , 2022, 63, 1166-1172.	0.5	4
145	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. <i>Protein and Peptide Letters</i> , 2020, 27, 1276-1287.	0.4	2
146	Molecular Pathology of Neuroendocrine Tumors. <i>Encyclopedia of Pathology</i> , 2021, , 1-3.	0.0	0
147	<i>Neue Arzneimittel 2019.</i> , 2020, , 43-150.		2

#	ARTICLE	IF	CITATIONS
148	Gastric Neuroendocrine Neoplasias: Literature Review. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 0, , .	0.2	0
149	Treatment of neuroendocrine liver metastases: a patent landscape review. Pharmaceutical Patent Analyst, 2020, 9, 29-32.	0.4	0
150	Differential diagnosis of solid pancreatic masses. Minerva Gastroenterologica E Dietologica, 2020, 66, 70-81.	2.2	10
151	Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. Hpb, 2022, 24, 681-690.	0.1	3
152	Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World Journal of Gastrointestinal Oncology, 2020, 12, 1031-1043.	0.8	8
154	Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?. European Journal of Cancer, Supplement, 2021, 16, 1-4.	2.2	0
155	Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines, 2021, 9, 1743.	1.4	7
156	What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers, 2021, 13, 5954.	1.7	3
157	177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1752-1763.	5.1	195
158	Challenges in treatment of a patient suffering from neuroendocrine tumor G1 of the hilar bile duct: a case report. BMC Gastroenterology, 2022, 22, 13.	0.8	1
159	Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open, 2022, 7, 100364.	2.0	25
160	Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. European Journal of Radiology, 2022, 147, 110119.	1.2	0
161	Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5%. European Journal of Radiology, 2022, 147, 110100.	1.2	1
162	Utility of Quantitative Metrics From Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma. American Journal of Roentgenology, 2022, 218, 999-1009.	1.0	7
163	Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics, 2022, 12, 280.	1.3	8
164	A Rare Case of Simultaneous Pheochromocytoma Accompanied with an Ileocecal Neuroendocrine Tumor. Case Reports in Oncology, 2022, 15, 27-33.	0.3	2
165	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2022, 169, 103572.	2.0	12
166	Combined liver-intestinal and multivisceral transplantation for neuroendocrine tumors extending beyond the liver: A systematic literature review. Transplantation Reviews, 2022, 36, 100678.	1.2	4

#	ARTICLE	IF	CITATIONS
167	Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?. <i>Abdominal Radiology</i> , 2022, 47, 1071-1081.	1.0	2
169	Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis. <i>Journal of Investigative Surgery</i> , 2022, 35, 1239-1247.	0.6	4
170	A Deep Learning-Based Segmentation System for Rapid Onsite Cytologic Pathology Evaluation of Pancreatic Masses: A Retrospective, Multicenter, Diagnostic Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
171	Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. <i>Current Oncology</i> , 2022, 29, 510-515.	0.9	8
172	Neuroendocrine tumors (NETs) – experience of a single Center. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 62, 457-463.	0.4	0
173	Faecal microbiome and metabolic signatures in rectal neuroendocrine tumors. <i>Theranostics</i> , 2022, 12, 2015-2027.	4.6	7
174	An abdominal wall neuroendocrine tumor of unknown primary origin: A case report and review of the literature. <i>Cancer Reports</i> , 2022, , e1610.	0.6	2
175	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 484-490.	1.1	8
176	Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987–2016. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	9
177	Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Cancers</i> , 2022, 14, 1119.	1.7	28
178	Rare Case of High Grade Neuroendocrine Carcinoma Found on Bone Marrow Biopsy: A Case Report. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 83-88.	0.4	0
179	Prognostic Evaluation of Patients with Rectal Neuroendocrine Neoplasms and Hepatic Metastases: A SEER Database Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
180	What Gastroenterologists Should Know about Carcinoid Syndrome. <i>Gastroenterology Insights</i> , 2022, 13, 127-138.	0.7	3
181	Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 115-125.	0.3	2
182	Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 843376.	1.3	2
183	Impact of tumor grade on pancreatic neuroendocrine tumors. <i>Asian Journal of Surgery</i> , 2022, 45, 2659-2663.	0.2	7
184	Rectal neuroendocrine neoplasms: what the radiologists should know. <i>Abdominal Radiology</i> , 2022, 47, 4016-4031.	1.0	3
185	Pancreas – Its Functions, Disorders, and Physiological Impact on the Mammals™ Organism. <i>Frontiers in Physiology</i> , 2022, 13, 807632.	1.3	19

#	ARTICLE	IF	CITATIONS
186	Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103648.	2.0	8
187	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196.	1.7	4
188	Risk Factors Associated with the Development of Metastases in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 60.	1.0	0
189	Radiomics in pancreatic cancer for oncologist: Present and future. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 356-361.	0.6	9
190	Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of the American College of Surgeons</i> , 2022, 234, 900-909.	0.2	2
191	Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Cancers</i> , 2022, 14, 2028.	1.7	6
192	High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1001-1013.	1.3	2
193	Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1670-1678.	0.9	5
194	A deep learning-based segmentation system for rapid onsite cytologic pathology evaluation of pancreatic masses: A retrospective, multicenter, diagnostic study. <i>EBioMedicine</i> , 2022, 80, 104022.	2.7	15
195	Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). <i>European Journal of Cancer</i> , 2022, 169, 1-9.	1.3	5
196	Highly variable biodistribution of <sup>68</sup> Ga labeled somatostatin analogues <sup>68</sup> Ga-DOTA-NOC and <sup>68</sup> Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 654-661.	0.7	1
197	Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 267-290.	0.4	5
198	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
199	HNF1A-AS1 <sup>745A</sup> tumor-associated long non-coding RNA. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	6
201	Flow-compensated diffusion encoding in MRI for improved liver metastasis detection. <i>PLoS ONE</i> , 2022, 17, e0268843.	1.1	5
202	Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2181-2187.	0.5	2
203	Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 383-396.	0.8	8
204	Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. <i>Cancer Imaging</i> , 2022, 22, .	1.2	5

#	ARTICLE	IF	CITATIONS
205	Gastric Neuroendocrine Tumor Treatment and Survival Outcome Depends on Facility Type. <i>American Surgeon</i> , 0, , 000313482211094.	0.4	0
206	Practical Considerations for Implementation of <sup>177</sup> Lu-DOTATATE Neuroendocrine Tumor Treatment Programs. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 195-202.	0.4	0
207	The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Cancers</i> , 2022, 14, 2911.	1.7	3
209	Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2022, 18, 66.	0.1	0
210	Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
211	Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. <i>Pharmaceutics</i> , 2022, 14, 1378.	2.0	10
212	Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. <i>European Radiology</i> , 2022, 32, 8317-8325.	2.3	4
213	Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	14
214	Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review. <i>Orthopaedic Surgery</i> , 2022, 14, 2766-2775.	0.7	0
215	Clinicopathological Features of Neuroendocrine Tumors in Gastroenteropancreatic Tract: A Single Center Study. <i>Cureus</i> , 2022, , .	0.2	0
216	Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
217	Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review. <i>Medicine (United States)</i> , 2022, 101, e29616.	0.4	2
218	Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
219	Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador. <i>Healthcare (Switzerland)</i> , 2022, 10, 1569.	1.0	3
220	The impact of COVID-19 on the management of neuroendocrine tumors (NETs): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	1
221	A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
222	A Combination of Preoperative Computed Tomography-Defined Sarcopenia and Systemic Inflammation on Survival in Patients with Poorly Differentiated Neuroendocrine Neoplasms Following Radical Resection. <i>Nutrition and Cancer</i> , 2023, 75, 186-196.	0.9	1
223	Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. , 2022, 10, e004854.		8

#	ARTICLE	IF	CITATIONS
224	Three-in-one incidence of hepatocellular carcinoma, cholangiocellular carcinoma, and neuroendocrine carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10575-10582.	0.3	1
225	Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. <i>Translational Oncology</i> , 2022, 25, 101526.	1.7	4
226	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114742.	2.6	1
227	S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. <i>EClinicalMedicine</i> , 2022, 54, 101667.	3.2	2
229	Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
230	Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5
231	Targeting receptor tyrosine kinases in neuroendocrine neoplasm: what's going on with lung carcinoids?. <i>Minerva Endocrinology</i> , 2022, 47, .	0.6	3
232	Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 4769.	1.7	3
233	New Mouse Model Suggests That Some Neuroendocrine Tumors May Originate From Neural Crest-Derived Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, , .	2.3	0
234	Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2022, 28, 4943-4958.	1.4	2
236	Comment on: development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-2.	0.6	0
237	RUNDC3A/SNAP25/Akt signaling mediates tumor progression and chemoresistance in gastric neuroendocrine carcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
238	Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine. <i>American Journal of Surgery</i> , 2023, 225, 58-65.	0.9	4
239	Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Biomedicines</i> , 2022, 10, 2660.	1.4	3
240	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
241	Nomogram for preoperative estimation of histologic grade in gastrointestinal neuroendocrine tumors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
243	Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1401-1419.	2.1	4
244	Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 16-32.	12.5	11



#	ARTICLE	IF	CITATIONS
245	Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours. <i>Annals of Surgical Oncology</i> , 2023, 30, 2988-2998.	0.7	3
246	Amino Acid Solutions for <sup>177</sup> Lu-Oxodotreotide Premedication: A Tolerance Study. <i>Cancers</i> , 2022, 14, 5212.	1.7	2
248	Physins in digestive system neoplasms. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
249	Growth Hormone-Releasing Hormone-Secreting Neuroendocrine Tumors. <i>Contemporary Endocrinology</i> , 2022, , 15-29.	0.3	0
250	Long-term clinical outcomes of endoscopic submucosal dissection in rectal neuroendocrine tumors based on resection margin status: a real-world study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 2644-2652.	1.3	3
251	Novel staging for gastric neuroendocrine neoplasms by incorporating the <sc>WHO</sc> grading into the <sc>TNM</sc> staging system. <i>Cancer Medicine</i> , 0, , .	1.3	0
252	MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1599-1609.	0.9	2
253	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
255	Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [ <sup>68</sup> Ga]DOTATATE PET/CT. <i>Radiology Case Reports</i> , 2023, 18, 481-485.	0.2	0
256	Molecular Pathology of Neuroendocrine Tumors. <i>Encyclopedia of Pathology</i> , 2022, , 129-130.	0.0	0
257	The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 267-282.	2.6	2
259	Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
260	Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics. <i>Journal of Clinical Medicine</i> , 2022, 11, 7456.	1.0	2
261	Quantitative characterization of duodenal gastrinoma autofluorescence using multiphoton microscopy. <i>Lasers in Surgery and Medicine</i> , 0, , .	1.1	1
262	Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis. <i>Endocrine</i> , 2023, 80, 221-230.	1.1	2
264	The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1373-1384.	1.8	2
266	Comparison of the efficacy of endoscopic submucosal dissection and transanal endoscopic microsurgery in the treatment of rectal neuroendocrine tumors ≤ 2 cm. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
267	Prediction of Pathological Grades of Pancreatic Neuroendocrine Tumors Based on Dynamic Contrast-Enhanced Ultrasound Quantitative Analysis. <i>Diagnostics</i> , 2023, 13, 238.	1.3	1



#	ARTICLE	IF	CITATIONS
268	Gastric Neuroendocrine Tumors According to the 2019 World Health Organization Grading System: A Single-Center, Retrospective Study. <i>Gut and Liver</i> , 2023, , .	1.4	0
269	Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. <i>Current Oncology</i> , 2023, 30, 1381-1394.	0.9	3
270	Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. <i>Surgery</i> , 2023, 173, 1045-1051.	1.0	1
271	Use of dual-layer spectral detector computed tomography in the diagnosis of pancreatic neuroendocrine neoplasms. <i>European Journal of Radiology</i> , 2023, 159, 110660.	1.2	4
272	Gastroenteropancreatic Neuroendocrine Tumor Diagnosis. <i>PET Clinics</i> , 2023, 18, 189-200.	1.5	3
273	The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses. <i>Cancers</i> , 2023, 15, 160.	1.7	0
274	An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. <i>Biomedicines</i> , 2023, 11, 303.	1.4	2
275	HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
276	Genetic alterations of Glâ€NECs involving three main signaling pathways. <i>Cancer Medicine</i> , 2023, 12, 8238-8250.	1.3	2
277	Resistance of neuroendocrine tumours to somatostatin analogs. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 33-52.	1.2	1
278	Neuroendocrine Neoplasms. <i>PET Clinics</i> , 2023, 18, 161-168.	1.5	2
279	Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
280	Association between autophagy and acute pancreatitis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
281	Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Control</i> , 2023, 30, 107327482311523.	0.7	1
282	Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study. <i>Gastroenterology Report</i> , 2022, 11, .	0.6	0
283	The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE. <i>Nuclear Medicine Communications</i> , 2023, 44, 509-517.	0.5	1
284	Comparable long-term survival outcomes of endoscopic therapy versus surgical therapy for T1-2N0M0 duodenal neuroendocrine tumors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 5444-5452.	1.3	1
285	An update on Merkel cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188880.	3.3	3

#	ARTICLE	IF	CITATIONS
286	Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades. <i>Endocrine Connections</i> , 2023, 12, .	0.8	2
287	A physiologically based pharmacokinetic model for [68Ga]Ga-(HA)-DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients. <i>EJNMMI Research</i> , 2023, 13, .	1.1	2
288	Pancreatic steatosis and its correlation with clinicopathological features in patients with pancreatic neuroendocrine neoplasms. <i>Journal of Pancreatology</i> , 0, Publish Ahead of Print, .	0.3	0
289	The potential application of MR-derived ADCmin values from 68Ga-DOTATATE and 18F-FDG dual tracer PET/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors. <i>EJNMMI Research</i> , 2023, 13, .	1.1	3
290	Liver transplantation in gastroenteropancreatic neuroendocrine tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
291	Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE. <i>Cancers</i> , 2023, 15, 1134.	1.7	4
292	What have we learnt from the past “ would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
293	Advances in Epidemiology, Diagnostics and Drug Treatment of Pancreatic Neuroendocrine Neoplasm. <i>Advances in Clinical Medicine</i> , 2023, 13, 1849-1859.	0.0	0
294	Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment. <i>PET Clinics</i> , 2023, 18, 215-221.	1.5	1
295	Nomograms for Predicting Survival Outcomes in Patients with Neuroendocrine Neoplasms of the Gallbladder Undergoing Primary Tumor Resection: A Population-Based Study. <i>Current Oncology</i> , 2023, 30, 2889-2899.	0.9	0
296	The upregulation of keratocan promotes the progression of human pancreatic cancer. <i>Molecular and Cellular Toxicology</i> , 2024, 20, 271-280.	0.8	1
297	Risk prediction of second primary malignancies in primary colorectal neuroendocrine neoplasms patients: a population-based study. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	1
298	Unique Characteristics of Patients with Von Hippelâ€“Lindau Disease Defined by Various Diagnostic Criteria. <i>Cancers</i> , 2023, 15, 1657.	1.7	1
301	MEN1 Degradation Induced by Neddylation and the CUL4Bâ€“DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression. <i>Cancer Research</i> , 2023, 83, 2226-2247.	0.4	4
303	Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States. <i>Chinese Medical Journal</i> , 2023, 136, 1216-1224.	0.9	3
304	Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre. <i>BMC Endocrine Disorders</i> , 2023, 23, .	0.9	0
305	Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 1047-1063.	2.0	2
318	Gastric NEN. III-1. Epidemiology (Including Risk Factor)/Pathologic and Molecular Characteristics. , 2023, , 437-441.		0

#	ARTICLE	IF	CITATIONS
367	GEP-NETs radiomics in action: a systematical review of applications and quality assessment. Clinical and Translational Imaging, 0, , .	1.1	0